AI Article Synopsis

  • The study investigates the impact of repeated HLA mismatches on kidney transplant outcomes in patients who previously received cardiothoracic transplants in the UK.
  • It found that 30% of patients had a repeat HLA mismatch, but demographics and immunosuppressive treatment were similar across groups.
  • Importantly, the research concluded that repeat mismatches did not negatively affect kidney function or survival rates at 1 and 5 years post-transplant.

Article Abstract

Background: Histocompatibility matching is not considered important in nonrenal solid organ transplants (NRSOT). There is no evidence to base guidance on whether mismatched human leukocyte antigen (HLA) antigens should be avoided in subsequent renal transplantation.

Methods: This study examines the effect of repeat HLA mismatches on renal allograft survival and function in all renal after cardiothoracic transplants undertaken in the United Kingdom between 1997 and 2003 using the UK Transplant data.

Results: A repeat HLA-A, -B, or -DR mismatch occurred in 16 of 53 (30%) cases. Recipients without a repeat mismatch were more likely to be male, but recipient age, donor age, recipient-donor age difference, donor gender, donor type, or cold ischemia time were comparable. Immunosuppressive therapy was similar in both groups. No differences were observed in renal allograft function at 1 or 5 years between the repeat mismatch group (estimated glomerular filtration rate [mean+/-standard deviation] 41.6+/-16.6 and 37.5+/-12.8 mL/min/1.73 m2) and the no repeat mismatch group (47.2+/-15.7 and 48.0+/-15.9 mL/min/1.73 m2). Renal allograft survival was also similar in the two groups at 1 and 5 years.

Conclusions: In this limited, heterogeneous, observational cohort of cardiothoracic transplant patients who went on to receive a sequential kidney transplant, a repeated HLA antigen mismatch was not associated with a detrimental effect on kidney transplant outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0b013e3181a60c51DOI Listing

Publication Analysis

Top Keywords

renal allograft
12
repeat mismatch
12
renal cardiothoracic
8
cardiothoracic transplant
8
allograft survival
8
mismatch group
8
kidney transplant
8
renal
6
repeat
6
transplant
5

Similar Publications

Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation.

Transpl Int

January 2025

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for General and Visceral Surgery, Berlin, Germany.

Kidney transplantation is the treatment of choice for end-stage organ failure. To improve transplantation outcomes, particularly of "marginal" organs from extended criteria donors (ECD), attempts have been made to therapeutically modulate donor or graft pre-transplantation. Anti-thymocyte globulin (ATG) has a history as lymphocyte-depleting, immunosuppressive drug for treating rejection episodes post transplantation.

View Article and Find Full Text PDF

Background: Over the last decade, the number of simultaneous heart-kidney transplants (SHKTs) has increased dramatically. There are few reports of renal allograft outcomes in these high acuity patients. The goal of the present study was to identify variables that were related to early adverse outcomes (EAOs), including delayed graft function (DGF), primary non-function (PNF), and renal allograft futility (RAF) after SHKTs.

View Article and Find Full Text PDF

The role of macrophages remains incompletely understood in kidney injury and repair. Their plasticity offers an opportunity to polarize them towards mediating injury resolution in both native and transplanted kidneys undergoing ischemia and/or rejection. Here, we show that infiltrating kidney macrophages augmented their AIF-1 expression after injury.

View Article and Find Full Text PDF

Microvascular inflammation (MVI) in kidney transplant biopsies is mainly associated with antibody-mediated rejection (AMR), sparking debate within the Banff Classification of Renal Allograft Pathology regarding its exclusivity. This study reviewed the literature on MVI in T cell-mediated rejection (TCMR) and analyzed MVI in our transplant population. We searched English publications in MEDLINE, Embase, Web of Science, Cochrane, and Google Scholar until June 2024, focusing on glomerulitis (g), peritubular capillaritis (ptc), or MVI in kidney transplant biopsies classified as TCMR.

View Article and Find Full Text PDF

Rationale & Objective: Nearly half of kidney transplant recipients develop allograft failure within 10 years of transplantation and experience high mortality, significant symptom burden, and complex communication challenges. These patients may benefit from palliative care, but palliative care is infrequently provided in this population. This study explores palliative care perceptions and needs among patients with poorly functioning and declining kidney allografts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!